Fundraising Fox

ReNetX Bio

New Haven, US · Delaware corporation · 2 known investors

Biotech

Founders & leadership

ES
Erika SmithFounder
GM
George MaynardExecutive

Board

DW
David WurzerBoard director
GH
Gregory HoBoard director
JP
John PuzissBoard director

Investors · 2

Connecticut InnovationsreportedNew Haven · $500K – $2M
Spring Mountain CapitalreportedNew York

Reported raises · per SEC filings

Form D private placements

$6.4M disclosed across 3 rounds · 2017–2019

▶$2.8MraisedSep 2020 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gregory HoDirector
  • Erika SmithExecutive Officer, Director
  • John PuzissDirector
  • George MaynardExecutive Officer
  • David WurzerDirector
Offering amount
$2.8M
Amount sold
$2.8M
First sale
Nov 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.2MraisedJul 2019 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David WurzerDirector
  • John PuzissDirector
  • Erika R. SmithExecutive Officer, Director
Offering amount
$3.2M
Amount sold
$3.2M
First sale
Mar 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$425KraisedDec 2017 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JOHN PUZISSDirector
  • DAVID WURZERDirector
  • ERIKA R. SMITHExecutive Officer, Director
Offering amount
$450K
Amount sold
$425K
First sale
Jul 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$3.1M
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2013$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

ReNetX Bio’s technology offers ray of hope for spinal cord injury patientshartfordbusiness.com · Sep 2021ReNetX Bio Closes Series A Funding - FinSMEsfinsmes.com · May 2018Melinta awarded $6.2M for superbug drugs; ReNetX Bio completes funding roundhartfordbusiness.com · May 2018New Haven-Based ReNetX Bio, Inc. Closes Series A Funding and Expands Upon New Haven Rootsprweb.com · May 2018ReNetX Bio initiates financing round for spinal cord injury technology trial : 7 highlights - Becker’s Spine Reviewbeckersspine.com · Jul 2017ReNetX Bio Launched to Advance Innovative Neuro-Regenerative Technology Developed at Yale Universityglobenewswire.com · Jul 2017

Frequently asked questions

Who founded ReNetX Bio?
ReNetX Bio was founded by Erika Smith.
Who are ReNetX Bio's investors?
ReNetX Bio's investors include Connecticut Innovations, Spring Mountain Capital.
How much funding has ReNetX Bio raised?
ReNetX Bio has disclosed $6.4M raised across 3 rounds.
Where is ReNetX Bio headquartered?
ReNetX Bio is headquartered in New Haven, US.